Tag: Lanifibranor
Inventiva announces positive results from the proof-of-concept Phase II clinical trial, LEGEND, combining lanifibranor and empagliflozin in patients with MASH/NASH and type 2 diabetes – 03/18/2024 at 9:00 p.m.
Daix (France), Long Island City (New York, United States), March 18, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Inventiva announces the resumption of screening in the Phase III clinical study, NATiV3, evaluating lanifibranor in NASH – 03/07/2024 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), March 7, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Inventiva announces a late breaker abstract and two additional abstracts on its lead drug candidate, lanifibranor, at the Liver Meeting™ 2023 organized by the AASLD – 11/06/2023 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), November 6, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Inventiva and Hepalys Pharma, Inc., sign an exclusive license agreement to develop and commercialize lanifibranor in Japan and South Korea – 09/20/2023 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), Tokyo (Japan), September 20, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in clinical development…
Inventiva obtains a new patent extending the intellectual property protection of its lead product candidate lanifibranor in the United States – 11/28/2022 at 22:00
A new patent issued in the United States by the USPTO protects the use of lanifibranor for the potential treatment of cirrhotic patients whose disease is at risk of progressing…
Inventiva obtains a new patent extending the intellectual property protection of its lead product candidate lanifibranor in the United States – 11/28/2022 at 22:00
Daix (France), Long Island City (New York, United States), November 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Inventiva: encouraging presentations for lanifibranor – 06/10/2022 at 08:22
(AOF) – Inventiva has announced the selection of three scientific abstracts for poster presentation at the International Liver Congress 2022 organized by the Association for the Study of the Liver…
Inventiva: selection of an abstract on Lanifibranor
(CercleFinance.com) – Inventiva announces the selection of an abstract on its Lanifibranor, for a presentation in plenary session at the third International Conference on Fatty Liver to be held from…